Squarepoint Ops LLC Boosts Holdings in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Squarepoint Ops LLC lifted its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 175.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 85,677 shares of the company's stock after acquiring an additional 54,576 shares during the period. Squarepoint Ops LLC owned 0.52% of Sensus Healthcare worth $593,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in shares of Sensus Healthcare in the 4th quarter worth $27,000. Barclays PLC bought a new stake in shares of Sensus Healthcare in the 4th quarter worth $35,000. BNP Paribas Financial Markets bought a new stake in shares of Sensus Healthcare in the 4th quarter worth $47,000. IFP Advisors Inc bought a new stake in shares of Sensus Healthcare in the 4th quarter worth $95,000. Finally, Man Group plc grew its position in Sensus Healthcare by 34.0% during the fourth quarter. Man Group plc now owns 59,338 shares of the company's stock valued at $411,000 after buying an additional 15,059 shares during the period. Institutional investors and hedge funds own 25.30% of the company's stock.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded down $0.11 on Friday, reaching $4.92. 42,737 shares of the company's stock were exchanged, compared to its average volume of 201,020. The firm has a market cap of $80.91 million, a price-to-earnings ratio of 12.30 and a beta of 1.30. Sensus Healthcare, Inc. has a 52 week low of $4.01 and a 52 week high of $9.33. The stock has a fifty day simple moving average of $4.63 and a 200-day simple moving average of $5.89.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). The business had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million. Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. As a group, sell-side analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SRTS. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Sensus Healthcare in a report on Friday, April 4th. Maxim Group decreased their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Finally, Wall Street Zen lowered shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Sensus Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $11.67.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.